Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Algernon Form 7 Monthly report dated April 6

<< Previous

Bullboard Posts

Next >>

Comment by Cookie2018on Apr 07, 2021 4:14pm

212 Views

Post# 32951196

RE:Algernon Form 7 Monthly report dated April 6

Sec Form F-7 Definitions and onwards and upwards...

https://www.investopedia.com/terms/s/sec-form-f-7.asp#:~:text=SEC%20Form%20F%2D7%20is,offering%20rights%20to%20U.S.%20investors.&text=This%20form%20is%20a%20wraparound,by%20securities%20regulation%20in%20Canada.

<< Previous

Bullboard Posts

Next >>

Cameco raises uranium output as Q3 results surge